Managing clinical trials in oncology has never been simple. It’s one of the most researched yet operationally demanding therapeutic areas in modern medicine. Narrow inclusion criteria, protocol complexity, and difficulties with patient recruitment are just a few of the hurdles Sponsors face — especially in multinational studies.
As the global demand for new cancer therapies accelerates, the pressure on biotech and pharma companies to deliver results faster has never been higher. Yet, the traditional hubs for research are becoming saturated. At Palleos, a leading mid-size full-service CRO in Europe, we’ve supported dozens of oncology studies across the region, helping Sponsors navigate these challenges with smarter, more grounded strategies. One of the most effective decisions a Sponsor can make early on is where to conduct the trial — and increasingly, Eastern Europe is proving to be the right answer.
One of the main reasons oncology trials fall behind schedule is recruitment. In Western Europe and the U.S., patients often have access to cutting-edge therapies through national healthcare systems or commercial availability. As a result, clinical trials can feel less urgent for both patients and physicians. Sites in these regions are often competing for the same small pool of patients, leading to delays that can cost Sponsors millions.
In contrast, many countries in Eastern Europe face a very different reality. Access to innovative cancer treatments is often limited, especially outside major urban centers. For many patients, participation in a clinical trial isn’t just an option — it’s the best or only viable treatment path. That changes everything. Sites see more interest, investigators are highly engaged, and timelines become more predictable.
However, volume isn’t the only metric that matters. Effective recruitment strategies in this region rely on the deep trust patients place in their physicians. In Eastern Europe, the relationship between oncologist and patient is often more centralized than in the fragmented systems of the West. When an investigator recommends a trial, patients listen. This leads not only to faster enrollment but also to significantly higher retention rates, ensuring the integrity of the study data from start to finish.
We often say that successful clinical trial execution is built on global standards but delivered through local expertise. That’s where Palleos adds value. With teams on the ground across Eastern Europe, we understand not just the regulations, but the people, the institutions, and the unwritten rules that define how trials run in practice.
For a Sponsor, navigating the diverse cultural and operational landscapes of Poland, Romania, Bulgaria, or Hungary can be daunting without a guide. Sponsors working with us benefit from a blend of strategic guidance and hands-on operational support — from site selection and startup to patient engagement, monitoring, and data collection. It’s not about ticking boxes. It’s about helping every project find its footing early and move forward with confidence.
This local intimacy is crucial for clinical operations. Knowing which university hospital has the right equipment for a specific biomarker study, or which Principal Investigator has the best track record for oncology studies in lung vs. breast cancer, allows us to build feasibility assessments based on reality, not just database metrics.
What about regulatory complexity? Eastern Europe has a reputation for strong regulatory systems that may seem unfamiliar at first glance, but they’re structured, logical, and surprisingly efficient when approached with experience.
The regulatory environment in Europe is undergoing a massive shift with the full implementation of the EU Clinical Trials Regulation (CTR). While this aims to harmonize processes, local nuances remain. Expert regulatory consulting is non-negotiable for Sponsors who want to avoid administrative bottlenecks. Our regulatory team helps Sponsors move from submissions to approvals with minimal friction — keeping studies in motion and Sponsors fully compliant.
We bridge the gap between the Sponsor’s scientific goals and the local Competent Authorities’ requirements. Whether it’s navigating ethics committee questions in Warsaw or aligning with submission deadlines in Bucharest, our team ensures that clinical trials in oncology don’t just get approved—they get approved on a timeline that keeps the commercial strategy on track.
Oncology trials generate more data, require longer follow-up, and often involve more complex logistics than other therapeutic areas. Add to that the pressure of ensuring regulatory compliance in multiple countries — and the need for a reliable, integrated approach becomes clear.
Palleos brings together biostatistics, project management, regulatory consulting, and clinical operations into one unified service model. We don’t just coordinate trials — we manage clinical trials with foresight, flexibility, and constant attention to quality.
And when mid-trial adjustments are needed? We move fast. Whether it’s modifying recruitment strategies, adapting protocol designs, or addressing site-level challenges — our structure allows us to respond without disruption. This agility is often missing in massive, global CROs, where change orders can take weeks to process. As a specialized partner, we act as an extension of the Sponsor’s team, ensuring that decisions made in the boardroom are executed effectively at the clinic level.
Modern oncology is increasingly becoming a game of precision medicine. As we move away from “one-size-fits-all” chemotherapy and toward targeted immunotherapies and gene therapies, the patient populations are becoming smaller and more specific. In many ways, modern oncology is beginning to resemble rare disease research.
This is where the Eastern European advantage shines brightest. Finding specific genetic mutations requires a vast funnel of patients. Because the healthcare systems in Eastern Europe are often centralized around large academic and public hospitals, a single site can have access to a massive database of patients. This centralization makes patient recruitment for niche indications far more feasible than in the decentralized U.S. model.
Consequently, Palleos has developed significant capabilities as a rare disease CRO operating within the oncology space. We know how to deploy recruitment strategies that find the “needle in the haystack” patients required for today’s complex protocols. Whether it is an orphan drug designation or a basket trial targeting a specific mutation across multiple tumor types, the density of the patient population in Eastern Europe provides a distinct strategic advantage.
Selecting an oncology CRO services provider is one of the most critical decisions a biotech can make. The wrong choice can lead to rescue studies, lost data, and burned bridges with investigators. The right choice leads to quality data, met deadlines, and a clear path to market.
For Sponsors looking to maximize their budget without compromising on quality, CRO oncology expertise in Eastern Europe offers the perfect balance. The region offers highly qualified medical staff, motivated patient populations, and data quality that stands up to scrutiny by the EMA and FDA.
At Palleos, we are proud to be the bridge between innovative Sponsors and the sites that can deliver their results. By combining deep clinical trial execution experience with regional mastery, we turn the potential of Eastern Europe into a competitive advantage for our clients. Oncology research is difficult, but with the right partner and the right location, it is a challenge we can meet together.
Oncology research isn’t slowing down — but it is shifting. Sponsors are looking for partners who combine expertise with practicality, who don’t overpromise but consistently deliver.
That’s exactly what Palleos is built for.
If you’re planning your next oncology trial, or considering expanding into Eastern Europe, we’d love to talk. As a full-service CRO in Europe, we offer consulting services, clinical research services, and full operational support tailored to the needs of oncology studies. Let’s make your next trial smoother, faster, and more focused — from the first feasibility call to final data lock.
Oncology research isn’t slowing down — but it is shifting. Sponsors are looking for partners who combine expertise with practicality, who don’t overpromise but consistently deliver.
That’s exactly what Palleos is built for.
If you’re planning your next oncology trial, or considering expanding into Eastern Europe, we’d love to talk. As a full-service CRO in Europe, we offer consulting services, clinical research services, and full operational support tailored to the needs of oncology studies. Let’s make your next trial smoother, faster, and more focused — from the first feasibility call to final data lock.
